Janux Therapeutics, Inc.
JANX
$28.80
$1.937.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -20.22M | -28.06M | -5.96M | -14.76M | -11.76M |
| Total Depreciation and Amortization | 512.00K | 510.00K | 506.00K | 532.00K | 531.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.32M | 12.49M | 2.78M | 3.84M | 2.42M |
| Change in Net Operating Assets | -345.00K | 12.83M | -7.35M | -4.45M | -1.10M |
| Cash from Operations | -16.73M | -2.23M | -10.02M | -14.84M | -9.90M |
| Capital Expenditure | -42.00K | -25.00K | -95.00K | -197.00K | -515.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 33.97M | 12.70M | -190.79M | -113.54M | 11.64M |
| Cash from Investing | 33.93M | 12.67M | -190.89M | -113.74M | 11.12M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 386.65M | 1.65M | 2.77M | 322.17M | 831.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 386.65M | 1.65M | 2.77M | 322.17M | 831.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 403.85M | 12.09M | -198.14M | 193.60M | 2.05M |
